About

Persistent, latent HIV infection despite anti-retroviral therapy (ART) remains a formidable barrier towards achieving an HIV cure. A major approach to target persistent HIV infection involves latency reversal, using small molecules capable of inducing expression of the HIV provirus, followed by immune mediated clearance of infected cells. The successful implementation of this or indeed any other approach to HIV eradication will require specific knowledge about the nature of the reservoir and the interplay of factors regulating the reservoir in all human populations. Women constitute one half of people living with HIV disease yet, they represent a minority in HIV cure studies. Our laboratory uses molecular biology and biochemical methods to 1) define sex-specific and other factors that contribute to HIV persistence in people living with HIV with a particular focus on women, 2) define modalities to disrupt latency and clear latently infected cells, and 3) apply these observations in clinical applications.

In the News

• 

  Archin Receives Diversity in Science and Excellence Award

  Nancie M. Archin, PhD, researcher with the Institute for Global Health and Infectious Diseases, and assistant professor of medicine in the division of infectious diseases, received the “Diversity in Science and Excellence” award from the International Society for Antiviral Research. The $5,000 award goes towards a scientist of any group historically underrepresented in the Society … Read more

• 

  IAMIGHID: Spotlighting the HIV Cure Team

  HIV/AIDS has been around for approximately 40 years, but many researchers say the end is in sight. The question is, will it be in our lifetime or just around the corner? This is a spotlight on the HIV CURE Center, comprising approximately 55 researchers and students, featuring David Margolis, MD, the director, Nancie Archin, PhD, a … Read more